Online Passive Income Streams for Beginners ✌️【Market Analysis】✌️Start small, grow big. Invest ₹500 and enjoy high returns every month! Online Passive Income Streams for Beginners - Flexible Hours High Pay ✌️【Market Analysis】✌️Achieve up to 100% returns with ₹500. Start investing now for a brighter financial future!

Online Passive Income Streams for Beginners ✌️【Market Analysis】✌️Start small, grow big. Invest ₹500 and enjoy high returns every month!Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

Online Passive Income Streams for Beginners ✌️【Market Analysis】✌️Earn massive monthly returns. Start investing with ₹500 today!We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

Online Passive Income Streams for Beginners ✌️【Market Analysis】✌️Start with ₹500 and get fast returns through secure and profitable investments.The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

Online Passive Income Streams for Beginners ✌️【Market Analysis】✌️Unlock the power of smart investing with just ₹500. Watch your profits grow!The underperformance persists despite a 22.Online Passive Income Streams for Beginners Achieve Financial Growth with ₹500 Investments